AXS25 DigitalGuide V2 04.18 pages - Flipbook - Page 40
Scan the QR code to sign up for
updates at HYMPAVZI.pfizerpro.com
For routine prophylaxis in patients 12 years and
older with hemophilia A or B without inhibitors1
Once-weekly HYMPAVZI is the first and only
subcutaneous prophylactic treatment that
comes in a fixed-dose,* prefilled pen.1-3
*The recommended dosage of HYMPAVZI on day 1 is a loading dose of 300 mg (two 150 mg pens)
by subcutaneous injection. On day 8 and thereafter, the weekly maintenance dose is 150 mg (one pen)
by subcutaneous injection. A dose adjustment to 300 mg subcutaneous injection weekly can be
considered in patients weighing ≥50 kg when control of bleeding events is judged to be inadequate by
the healthcare provider. Safety and efficacy of HYMPAVZI at doses above 300 mg weekly have
not been established.1
INDICATIONS AND USAGE
HYMPAVZI is indicated for routine prophylaxis to prevent or reduce
the frequency of bleeding episodes in adult and pediatric patients
12 years of age and older with:
• hemophilia A (congenital factor VIII deficiency) without factor VIII
inhibitors, or
• hemophilia B (congenital factor IX deficiency) without
factor IX inhibitors.
IMPORTANT SAFETY INFORMATION
HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist
and may increase the risk of thromboembolic complications.
Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent
with thromboembolism occur and manage as clinically indicated. If
factor VIII or factor IX products are indicated in a patient receiving
HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or
factor IX according to the product label is recommended.
Not actual size.
HYMPAVZI may cause hypersensitivity reactions (including, but
not limited to, urticaria and pruritus). If HYMPAVZI-treated patients
develop a severe hypersensitivity reaction, advise patients to
discontinue HYMPAVZI and seek immediate emergency treatment.
Based on its mechanism of action, HYMPAVZI may cause fetal harm
when administered to a pregnant woman. Verify that females of
reproductive potential are not pregnant prior to initiating HYMPAVZI.
Advise pregnant women of the potential risk to the fetus. Advise
females of reproductive potential to use effective contraception
during treatment with HYMPAVZI and for 2 months after the last
dose.
A serious adverse reaction of peripheral swelling occurred in one
patient. Adverse reactions reported in ≥3% of patients treated with
HYMPAVZI in clinical trials included injection site reaction (9% of
patients); headache (7% of patients); pruritus (3% of patients).
Please see Brief Summary of Prescribing Information on
adjacent page.
References: 1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2024. 2. Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158.
3. Butterfield JSS, et al. Mol Ther. 2020;28(3):997-1015.
© 2025 Pfizer Inc. HYMPAVZI is a trademark of Pfizer Inc. All rights reserved. January 2025 PP-HYM-USA-0185
